Harbor Capital Advisors Inc. Lowers Stake in Certara, Inc. (NASDAQ:CERT)

Harbor Capital Advisors Inc. trimmed its position in Certara, Inc. (NASDAQ:CERT) by 13.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,460 shares of the company’s stock after selling 2,684 shares during the quarter. Harbor Capital Advisors Inc.’s holdings in Certara were worth $186,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Choreo LLC purchased a new position in Certara in the second quarter valued at approximately $348,000. Oppenheimer Asset Management Inc. increased its position in shares of Certara by 45.7% in the second quarter. Oppenheimer Asset Management Inc. now owns 197,724 shares of the company’s stock worth $2,738,000 after acquiring an additional 61,980 shares in the last quarter. Envestnet Asset Management Inc. increased its position in shares of Certara by 8.2% in the second quarter. Envestnet Asset Management Inc. now owns 573,660 shares of the company’s stock worth $7,945,000 after acquiring an additional 43,403 shares in the last quarter. Massachusetts Financial Services Co. MA raised its stake in shares of Certara by 9.8% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,773,892 shares of the company’s stock valued at $38,418,000 after acquiring an additional 248,448 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Certara by 9.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 3,079,023 shares of the company’s stock valued at $42,643,000 after acquiring an additional 273,095 shares in the last quarter. 73.96% of the stock is owned by institutional investors and hedge funds.

Certara Stock Performance

NASDAQ:CERT opened at $11.96 on Thursday. The firm has a 50-day moving average of $10.86 and a two-hundred day moving average of $11.95. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The stock has a market cap of $1.93 billion, a P/E ratio of -59.80, a PEG ratio of 5.86 and a beta of 1.52. Certara, Inc. has a 1-year low of $9.41 and a 1-year high of $19.87.

Certara (NASDAQ:CERT) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The firm had revenue of $94.80 million during the quarter, compared to the consensus estimate of $95.51 million. During the same quarter in the prior year, the business posted $0.06 earnings per share. Certara’s revenue for the quarter was up 10.7% on a year-over-year basis. On average, research analysts expect that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Barclays lowered their price target on Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a report on Thursday, November 7th. Robert W. Baird decreased their target price on Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research report on Tuesday, November 5th. Finally, UBS Group upgraded Certara from a “neutral” rating to a “buy” rating and set a $16.00 target price on the stock in a report on Friday, September 27th. Six analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, Certara has a consensus rating of “Hold” and a consensus target price of $15.92.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.